Acrivon Therapeutics Inc. (ACRV) NASDAQ

$7.11 0.65 (9.98%)

Market Cap: $143.49M

As of 03/28/24 03:59 PM EDT. Market closed.

(ACRV)

Acrivon Therapeutics Inc. (ACRV)
NASDAQ

$7.11
0.65 (9.98%)

Market Cap: $143.49M

As of 03/28/24 03:59 PM EDT. Market closed.

Add to Portfolio

acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the ... read more

acrivon therapeutics is a biotech company specializing in drug development through early clinical treatment success using our unique predictive biomarker approach. our technology platform is based on integrating drug-regulated, global proteomics with focused intact tissue digital imaging to develop drug-tailored biomarker signatures for prospective patient responder identification. the foundational science is based on proven, pathway-based methods linking active disease-driving mechanisms with the drug mechanism-of-action, to precisely match the therapy with patients who will benefit. our method is applicable across drug modalities read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
42
URL
Address
.
PRICE CHART FOR ACRIVON THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$6.66
Previous Close
$6.47
Days Range
$6.05 - $6.56
52 week range
$3.19 - $14.39
Volume
127,822
Avg. Volume (30 days)
88,636
Market Cap
$143.49M
Dividend Yield
-
P/E
-
Shares Outstanding
22,194,307
Open
$6.66
Previous Close
$6.47
Days Range
$6.05 - $6.56
52 week range
$3.19 - $14.39
Volume
127,822
Avg. Volume (30 days)
88,636
Market Cap
$143.49M
Dividend Yield
-
P/E
-
Shares Outstanding
22,194,307
FINANCIAL STATEMENTS FOR ACRIVON THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ACRIVON THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Miller MaryChief Legal OfficerFeb 14, 2024 Option Exercise$3.4021773840,451Feb 16, 2024, 05:14 PM
Masson KristinaEVP - Business OperationsFeb 14, 2024 Option Exercise$3.405791,969318,226Feb 16, 2024, 05:13 PM
Holm-Jorgensen RasmusChief Financial OfficerFeb 14, 2024 Option Exercise$3.404341,47627,626Feb 16, 2024, 05:12 PM
Gamelin ErickChief Development OfficerFeb 14, 2024 Option Exercise$3.404681,59118,167Feb 16, 2024, 05:10 PM
Devroe EricChief Operating OfficerFeb 14, 2024 Option Exercise$3.407232,45859,710Feb 16, 2024, 05:08 PM
Blume-Jensen PeterPresident and CEOFeb 14, 2024 Option Exercise$3.4041,861142,3272,616,812Feb 16, 2024, 05:06 PM
Miller MaryChief Legal OfficerJan 17, 2024 Option Exercise$4.356522,83640,668Jan 19, 2024, 04:24 PM
Miller MaryChief Legal OfficerNov 14, 2023 Option Exercise$5.087353,73441,320Nov 16, 2023, 07:43 PM
Masson KristinaEVP - Business OperationsNov 14, 2023 Option Exercise$5.081,9009,652318,805Nov 16, 2023, 07:42 PM
Holm-Jorgensen RasmusChief Financial OfficerNov 14, 2023 Option Exercise$5.081,4707,46828,060Nov 16, 2023, 07:42 PM
Gamelin ErickChief Medical OfficerNov 14, 2023 Option Exercise$5.081,3957,08718,635Nov 16, 2023, 07:41 PM
Devroe EricChief Operating OfficerNov 14, 2023 Option Exercise$5.082,45012,44660,433Nov 16, 2023, 07:41 PM
Blume-Jensen PeterPresident and CEONov 14, 2023 Option Exercise$5.08239,0231,214,2372,658,673Nov 16, 2023, 07:41 PM
Miller MaryChief Legal OfficerOct 17, 2023 Option Exercise$5.482,23212,23142,055Oct 19, 2023, 07:45 PM
Chione Ltd10% OwnerJun 26, 2023 Sale$12.93162073,848,632Jun 28, 2023, 03:47 PM
Holm-Jorgensen RasmusChief Financial OfficerJun 16, 2023 Option Exercise$3.639,50034,48529,530Jun 20, 2023, 05:21 PM
Chione Ltd10% OwnerJun 15, 2023 Sale$12.142,05624,9603,848,648Jun 20, 2023, 05:15 PM
Chione Ltd10% OwnerJun 14, 2023 Sale$12.1389310,8323,850,704Jun 14, 2023, 06:33 PM
Chione Ltd10% OwnerJun 13, 2023 Sale$12.303,00036,9003,851,597Jun 14, 2023, 06:33 PM
Chione Ltd10% OwnerJun 12, 2023 Sale$12.342,00024,6803,854,597Jun 14, 2023, 06:33 PM
Devroe EricChief Operating OfficerJun 05, 2023 Option Exercise$1.049,2259,59462,883Jun 06, 2023, 04:15 PM
Blume-Jensen PeterPresident and CEOMay 31, 2023 Option Exercise$3.8833,605130,3872,403,702Jun 01, 2023, 08:40 PM
Chione Ltd10% OwnerNov 17, 2022 Buy$12.50400,0005,000,0003,856,597Nov 21, 2022, 06:26 PM
RA CAPITAL MANAGEMENT, L.P.DirectorNov 17, 2022 Buy$12.503,389,50042,368,7504,384,206Nov 21, 2022, 04:31 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Miller MaryChief Legal Officer02/14/2024738
Masson KristinaEVP - Business Operations02/14/20241,969
Holm-Jorgensen RasmusChief Financial Officer02/14/20241,476
Gamelin ErickChief Development Officer02/14/20241,591
Devroe EricChief Operating Officer02/14/20242,458
Blume-Jensen PeterPresident and CEO02/14/2024142,327
Miller MaryChief Legal Officer01/17/20242,836
Miller MaryChief Legal Officer11/14/20233,734
Masson KristinaEVP - Business Operations11/14/20239,652
Holm-Jorgensen RasmusChief Financial Officer11/14/20237,468
Gamelin ErickChief Medical Officer11/14/20237,087
Devroe EricChief Operating Officer11/14/202312,446
Blume-Jensen PeterPresident and CEO11/14/20231,214,237
Miller MaryChief Legal Officer10/17/202312,231
Chione Ltd10% Owner06/26/2023207
Holm-Jorgensen RasmusChief Financial Officer06/16/202334,485
Chione Ltd10% Owner06/15/202324,960
Chione Ltd10% Owner06/14/202310,832
Chione Ltd10% Owner06/13/202336,900
Chione Ltd10% Owner06/12/202324,680
Devroe EricChief Operating Officer06/05/20239,594
Blume-Jensen PeterPresident and CEO05/31/2023130,387
Chione Ltd10% Owner11/17/20225,000,000
RA CAPITAL MANAGEMENT, L.P.Director11/17/202242,368,750
Load More Insider Transactions
FUNDS WITH A POSITION IN ACRIVON THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
RA CAPITAL MANAGEMENT, L.P.4,810,5080.37%No changeOther
BLACKROCK INC.565,8320.00007%7.01%Other
GEODE CAPITAL MANAGEMENT, LLC189,2000.0001%-0.19%Other
UBS OCONNOR LLC93,4430.03%-11.01%Value
D. E. SHAW & CO., INC.31,9390.00014%-31.68%Other
CHANGE IN SHARES OUTSTANDING FOR ACRIVON THERAPEUTICS INC
STOCK BUYBACKS FOR ACRIVON THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.50%
1Q
09/30/2023
03/31/2023
0.73%
2Q

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.50%
1Q
03/31/2023
0.73%
2Q
BUYBACK ANNOUNCEMENT(S) FOR ACRIVON THERAPEUTICS INC
LOADING...